FNY Investment Advisers’s Cytokinetics CYTK Stock Holding History

FNY Investment Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2,000	Closed	-$170K	–	815
2026 Q2	$170K	Sell	2,000 -7,030	-78%	-$505K	0.06%	260
2026 Q1	$595K	Buy	9,030 +3,770	+72%	+$240K	0.26%	96
2025 Q4	$334K	Sell	5,260 -3,354	-39%	-$209K	0.09%	175
2025 Q3	$473K	Sell	8,614 -4,281	-33%	-$176K	0.15%	168
2025 Q2	$426K	Buy	12,895 +2,040	+19%	+$71K	0.18%	136
2025 Q1	$436K	Sell	10,855 -3,690	-25%	-$170K	0.27%	85
2024 Q4	$684K	Buy	14,545 +3,240	+29%	+$168K	0.35%	67
2024 Q3	$596K	Sell	11,305 -768	-6%	-$42.8K	0.29%	89
2024 Q2	$654K	Buy	12,073 +2,018	+20%	+$122K	0.44%	47
2024 Q1	$704K	Buy	+10,055	New	+$778K	0.42%	59

Other funds holding CYTK

MCP

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

NVWM LLC Yardley, Pennsylvania $533M AUM 27.53% 1-Year Est. Return

Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

BCG

Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return

FNY Investment Advisers's CYTK Position: Q3 2026 in Review

FNY Investment Advisers sold out of Cytokinetics (CYTK) in Q3 2026, closing a stake of 2,000 shares — an estimated $170K sold.

FNY Investment Advisers first reported a position in CYTK in Q1 2024 and held it in 10 quarters. The position peaked at $704K in Q1 2024. 26 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

FNY Investment Advisers reported no remaining Cytokinetics position as of Q3 2026 after selling out during the quarter.
FNY Investment Advisers sold 2,000 Cytokinetics shares in Q3 2026, an estimated $170K.
FNY Investment Advisers first reported a position in Cytokinetics in Q1 2024 and held it in 10 quarters.
FNY Investment Advisers's Cytokinetics position peaked at $704K in Q1 2024.
26 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on FNY Investment Advisers's 13F filing for Q3 2026, filed 16 Oct 2026.